Immuneering Corp - 8-K Filing
Immuneering reports Q3 2026 net loss of $24.2 million and extends Phase 2 pancreatic cancer trial follow-up due to improved patient survival. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $IMRX
Read the full article at SEC EDGAR
Part of the story Crescent Capital BDC Reports Q3 2026 Earnings with Increased Net Investment Income (48 articles)